This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Randomized, Masked Comparison of Bromfenac and Besifloxacin BID With Either Prednisolone BID or Loteprednol 0.5% BID for Prevention of Retinal Thickening and CME Following Phacoemulsification

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified June 2012 by Innovative Medical.
Recruitment status was:  Recruiting
Sponsor:
Information provided by:
Innovative Medical
ClinicalTrials.gov Identifier:
NCT01193504
First received: August 31, 2010
Last updated: June 13, 2012
Last verified: June 2012
History of Changes
  Purpose
The purpose of this study is to determine if Lotemax eye drops are at least as effective as Pred Forte eye drops, which are the standard of care after cataract surgery.

Condition Intervention Phase
Pseudophakia Cataract Surgery Drug: Pred Forte Drug: Lotemax Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single Blind (Investigator)
Primary Purpose: Prevention
Official Title: Randomized, Masked Comparison of Bromfenac and Besifloxacin BID With Either Prednisolone BID or Loteprednol 0.5% BID for Prevention of Retinal Thickening and CME Following Phacoemulsification

Resource links provided by NLM:

MedlinePlus related topics: Cataract
U.S. FDA Resources

Further study details as provided by Innovative Medical:

Primary Outcome Measures:
  • Prevention Of Retinal Thickening [ Time Frame: 1 Year ]
    • OCT (optical coherence tomography) with macular thickening
    • Incidence of CME ( cystoids macular edema)
    • BCVA (best corrected visual acuity)
    • UCVA (uncorrected visual acuity)
    • Central corneal thickness
Estimated Enrollment: 100
Study Start Date: September 2010
Estimated Study Completion Date: October 2012
Estimated Primary Completion Date: October 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Pred Forte
Patients scheduled to undergo phacoemulsification will be randomized in a 1:1 schedule to receive Pred Forte BID for 4 weeks postop. All patients will receive Xibrom BID for one month and Besifloxacin BID for 7 to 10 days postop.
 Drug: Pred Forte
Pred Forte BID for 4 weeks postop
Active Comparator: Lotemax
patients scheduled to undergo phacoemulsification will be randomized in a 1:1 schedule to receive Lotemax BID for 4 weeks postop. All patients will receive Xibrom BID for one month and Besifloxacin BID for 7 to 10 days postop.
 Drug: Lotemax
Lotemax BID for 4 weeks postop.

Detailed Description:
Prednisolone 1%, a topical steroid, is considered standard of care following cataract surgery to reduce inflammation. We aim to determine if Lotemax is at least as effective as Prednisolone. If so, these findings would demonstrate that physicians have other treatment options to consider.
  Eligibility
Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Male or female >18 years of age scheduled to undergo cataract surgery
  • Patients with systemic diseases will be enrolled only if there are no ocular manifestations of their disease (e.g. diabetics with normal retinal exams)
  • Expected visual outcome of BCVA (best corrected visual acuity)> 20/25 postoperatively, as determined by potential visual acuity testing and review of preoperative corneal topography and OCT (optical coherence tomography).
  • Ability to provide informed consent, take study medications as directed, and likely to complete all study visits

Exclusion Criteria:

  • Known contraindication to any study medication or any of their components
  • Required use of ocular medications other than the study medications during the study
  • Evidence of macular disease (Epiretinal membrane, Vitreomacular traction syndrome, macular hole) on preoperative OCT (optical coherence tomography)
  • Presence of significant dry macular degeneration that may impact postoperative visual results.
  • History of retinal vein occlusion or diabetic macular edema, uveitis or any macular disease predisposing them to cystoid macular edema or prolonged intraocular inflammation.
  • Posterior capsule rupture, Vitreous loss during surgery or any other complication that in the surgeon's opinion, could reduce potential for targeted visual outcome
  • Anticipated need for mechanical iris dilating devices
  • Presence of Epithelial Basement Membrane Dystrophy, significant dry eye, significant blepharitis, or any other corneal condition that may impact BCVA (best corrected visual acuity) postoperatively
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01193504

Contacts
Contact: Jenna Piel (951)653-5566 j.piel@imedsonline.com

Locations
United States, California
Harvard Eye Associates Recruiting
Laguna Hills, California, United States, 92653
Contact: Melissa Earl    951-653-5566    m.earl@imedsonline.com   
Contact: Annie Christensen    (951)653-5566    a.christensen@imedsonline.com   
Principal Investigator: John Hovanesian, MD         
United States, Florida
The Center For Excellence in Eye care Recruiting
Miami, Florida, United States, 33176
Contact: Melissa Earl    951-653-5566    m.earl@imedsonline.com   
Contact: Annie Christensen    (951)653-5566    a.christensen@imedsonline.com   
Principal Investigator: William Trattler, MD         
Sub-Investigator: Carlos Buznego, MD         
United States, Massachusetts
Ophthalmic Consultants of Boston Completed
Waltham, Massachusetts, United States, 02451
Sponsors and Collaborators
Innovative Medical
Investigators
Principal Investigator: William Trattler, MD The Center for Excellence in Eye Care
Principal Investigator: John Hovanesian, MD Harvard Eye Associates
Principal Investigator: Bonnie Henderson, MD Ophthalmic Consultants of Boston
  More Information

Responsible Party: Dr. William Trattler, The Center for Excellence in Eye care
ClinicalTrials.gov Identifier: NCT01193504     History of Changes
Other Study ID Numbers: 25324
Study First Received: August 31, 2010
Last Updated: June 13, 2012

Keywords provided by Innovative Medical:
Prevention of Retinal Thickening and CME Following Phacoemulsification
Pseudophakia following cataract surgery

Additional relevant MeSH terms:
Cataract
Pseudophakia
Lens Diseases
Eye Diseases
Signs and Symptoms
Polystyrene sulfonic acid
Loteprednol Etabonate
Prednisolone acetate
Methylprednisolone acetate
Bromfenac
Prednisolone
Methylprednisolone
Methylprednisolone Hemisuccinate
Prednisolone hemisuccinate
Prednisolone phosphate
 7-(3-aminohexahydro-1H-azepin-1-yl)-8-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid
Fluoroquinolones
Chelating Agents
Sequestering Agents
Molecular Mechanisms of Pharmacological Action
Anti-Allergic Agents
Anti-Inflammatory Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Antiemetics
Autonomic Agents

ClinicalTrials.gov processed this record on June 28, 2017